SDIX (SDIX) Announces Expansion of IVD Reagents Portfolio
8/3/2011 8:51:00 AM
NEWARK, Del.--(BUSINESS WIRE)--SDIX (NASDAQ: SDIX), a leading provider of In Vitro Diagnostic (IVD) reagents, announced the addition of nine new polyclonal antibodies to its product line for the IVD market while exhibiting at AACC last week. These products include Apo A1, Lp(a), HPT, CER, IgM, IgG(Fc), IgA, C3 and C4. The antibodies can be customized for in vitro diagnostics and will be available as antisera and in fractionated forms. The nine new products complement the existing SDIX IVD product line, which includes Troponin I, Strep A, CRP, ApoB and Albumin.